Incretins, including GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), are hormones naturally released by the gut during meals. They stimulate insulin secretion ...
KO-7246 regenerated functional β-cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models - ...
Asianet Newsable on MSN
Nasdaq futures tread water after Monday rout: MU, NVTS, NVO, KOD, SMMT, ASTS stocks in focus
On Stocktwits, retail sentiment toward SPY and QQQ stayed ‘bullish.’ ...
Novo Nordisk secures licensing rights to Hengrui's experimental GLP-1 pill for weight management, enhancing its portfolio in ...
9月27日，华东医药公布卡维列隆（HDM1002）中国减重Ⅲ期顶线结果： 每日口服400 mg，第52周平均体重较基线下降12.2% 。 公司已完成上市申请前沟通，准备递交体重管理适应症的上市申请。 卡维列隆所处的市场，已有疗效得到验证的口服药；注射端则有获批的GIP/GLP-1、GLP-1/胰高血糖素受体双靶点药物，以及仍在开发的三靶点产品。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results